Search clinical trials for: tumor response rate

Total 49538 results

Fujian Medical University

Recruiting

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Overall Response Rate

China
Erasmus Medical Center

Not yet recruiting

Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study

Pathological Response Rate, Circulating Tumour DNA
Jiangxi Provincial Cancer Hospital

Recruiting

High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor (ST-CR01)

Metastatic Cancer

China
The First Affiliated Hospital of Nanchang University
Shanghai Dengding BioAI Co.

Recruiting

Using Neoantigen Peptide Vaccine/Neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
Hospices Civils de Lyon

Recruiting

Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma (Mel-ImmAdj)

Melanoma

France
National Cancer Institute (NCI)

Recruiting

M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Colorectal Neoplasms | Colorectal Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bile Duct Neoplasms | Metastatic Colorectal Cancer (Mcrc) | Intrahepatic Cholangiocarcinoma (Icc) | Intrahepatic Bile Duct Cancer

United States
Centre Leon Berard

Recruiting

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)

Metastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)

France
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
Taproot Health

Recruiting

The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)

Melanoma | Sarcoma | Kidney Cancer | Adenocarcinoma | Renal Cell Carcinoma | Cervical Cancer | Acute Myeloid Leukemia | Stomach Cancer | Breast Cancer | Head and Neck Neoplasms | Nasopharyngeal Carcinoma | Glioblastoma | Astrocytoma | Multiple Myeloma | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer and other conditions

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

TILA-TACE in Treatment of Hepatocellular Carcinoma

Overall Survival | Tumor Response Rate

China
Peking Union Medical College Hospital
OrigiMed

Recruiting

Real-world Study for Patients With Advanced Hepatobiliary Tumors

Quality of Life | Objective Response Rate | Overall Survival | Progression-free Survival | Disease Control Rate | Duration of Response | Five-year Survival Rate

China
National Cancer Institute (NCI)

Recruiting

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

Colorectal Cancer | Liver Metastases | Colorectal Carcinoma | Colorectal Adenocarcinoma | Colorectal Cancer With Hepatic Metastases

United States
National Cancer Institute (NCI)

Active, not recruiting

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Neurofibromatosis 1 | Neurofibroma, Plexiform | Neurofibromatosis Type 1 | NF1

United States
Karyopharm Therapeutics Inc

Active, not recruiting

A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis

Myelofibrosis

Spain, China, Poland, United States, France, Greece, Italy
NantCell, Inc.
National Cancer Institute (NCI)

Completed

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

Chordoma

United States
Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial (FIL-RougeBIO)

Hodgkin Lymphoma

Italy
Oncolytics Biotech
PrECOG, LLC.

Active, not recruiting

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Breast Cancer Metastatic

United States
University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Active, not recruiting

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes (TRIABETES)

Obesity | Type 2 Diabetes Mellitus

United States
Taipei Veterans General Hospital, Taiwan
National Tsing Hua University,Taiwan

Completed

Boron Neutron Capture Therapy (BNCT) for Locally Recurrent Head and Neck Cancer (BNCT)

Head and Neck Cancer

Taiwan
Novartis Pharmaceuticals

Completed

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Melanoma | Cancer

Taiwan, Thailand, China, Hong Kong, Korea, Republic of
Amgen

Completed

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (TVEC-325)

Unresected Stage IIIb to IVM1c Melanoma

France, Poland, Italy, Russian Federation, Netherlands, Spain, United States, Austria, Belgium, United Kingdom, Germany, Hungary, Greece
Bayer

Completed

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, China, Hong Kong, Switzerland, Japan, France, Spain, Germany, United States, Austria, Czechia, United Kingdom, Korea, Republic of, Thailand, New Zealand, Hungary, Israel, Italy, Taiwan, Singapore, Turkey
Bayer

Completed

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, France, Switzerland, Germany, United States, Austria, New Zealand, Hungary, Korea, Republic of, Italy, Hong Kong, Thailand, Spain, Taiwan, Japan, Czechia, United Kingdom
Novartis Pharmaceuticals

Completed

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Metastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...

Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
Lei Li

Unknown

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Chemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 Antibody

China
Seoul National University Hospital

Unknown

The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study

Bladder Cancer

Korea, Republic of
Seoul National University Hospital

Completed

Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

Korea, Republic of
Peking University People's Hospital
Peking University; Northwestern University; University of Chicago

Unknown

Epigenetic Biomarker for Osteosarcoma

Histologic Response (Tumor Necrosis Rate) | Objective Response Rate for Neoadjuvant Chemotherapy, ORR | Progression-free Survival, PFS | Overall Survival, OS

China
Eli Lilly and Company
Parexel

Completed

Study of IMC-11F8 in Participants With Advanced Solid Tumors

Neoplasms

Japan
National Cancer Institute (NCI)

Completed

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

Melanoma

United States
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NAPSPAC)

Advanced Pancreatic Cancer

China
Centre Leon Berard
GlaxoSmithKline

Completed

Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)

GIST

France
Milad Hospital

Completed

Response Rate and Side Effects of Preoperative Chemotherapy (TOX Regimen) in Patients With Locally Advanced Operable Gastric Adenocarcinoma (TOX)

Gastric Cancer

Iran, Islamic Republic of
Fudan University

Completed

Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC

Gastric Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer

Locally Advanced Malignant Neoplasm

China
Liaoning Tumor Hospital & Institute

Unknown

Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

Colorectal Cancer | Liver Metastases

China
National Cancer Institute (NCI)

Completed

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Metastatic Melanoma | Metastatic Kidney Cancer

United States
Fudan University

Completed

Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Catholic University of the Sacred Heart

Completed

Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients (carbo-cox2)

Ovarian Neoplasms

Italy
Fudan University

Suspended

Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer

Gastric Cancer

China
Fudan University

Completed

Study of Cetuximab to Treat Gastric Cancer (STAGE)

Gastric Cancer

China
Celgene Corporation

Terminated

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States, Canada, Australia
Fudan University

Terminated

Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Fudan University

Terminated

Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)

Ewing's Sarcoma

China
Memorial Sloan Kettering Cancer Center
NeuroEndocrine Tumor Research Foundation (NETRF)

Recruiting

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Neuroendocrine Tumors

United States
Chimei Medical Center
E-DA Hospital

Not yet recruiting

Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis (MDC-S)

Sepsis | Critically Ill | Critical Care | Mortality Rate
S.LAB (SOLOWAYS)
Center of New Medical Technologies

Not yet recruiting

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Breast Cancer

Russian Federation
Tang-Du Hospital

Recruiting

Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

Lung Squamous Cell Carcinoma | Neoadjuvant Chemoimmunotherapy | Tumor Microenvironment

China
University Hospital, Lille

Not yet recruiting

Evaluation of Autonomic Nervous System Changes in Response to Stimulation by Sacral Neuromodulation (ESTIME)

Sacral Neuromodulation | Bladder Hyperactivity

Search clinical trials for: tumor response rate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations